These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28420989)

  • 1. FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines.
    Liberti L; Bujar M; Breckenridge A; Hoekman J; McAuslane N; Stolk P; Leufkens H
    Front Pharmacol; 2017; 8():161. PubMed ID: 28420989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
    Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
    Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU.
    Demirci E; Omes-Smit G; Zwiers A
    Clin Transl Sci; 2023 Jul; 16(7):1127-1133. PubMed ID: 37013379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.
    Kajiwara E; Shikano M
    Ther Innov Regul Sci; 2020 Jul; 54(4):814-820. PubMed ID: 32557300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways.
    Liberti L; McAuslane N; Stolk P; Breckenridge A; Leufkens H
    Ther Innov Regul Sci; 2020 Jan; 54(1):55-68. PubMed ID: 32008253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Survey of Industry Perceptions of Facilitated Regulatory Pathways in Drug Development in Australia.
    Yoffe A; Liu J; Smith G; Chisholm O
    Pharmaceut Med; 2023 Sep; 37(5):385-394. PubMed ID: 37368166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions.
    Bujar M; McAuslane N; Liberti L
    Pharmaceut Med; 2021 Mar; 35(2):113-122. PubMed ID: 33537899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation.
    Herink MC; Johnston K; Breninger K; Wu E; Irwin AN
    Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of expedited programs in the United States, as foreign regulatory factors, on clinical development time in Japan.
    Tajima G; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2022 Sep; 47(9):1395-1401. PubMed ID: 35488803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine.
    Kantor A; Haga SB
    J Pers Med; 2021 Jan; 11(1):. PubMed ID: 33466644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerating access to new medicines: Current status of facilitated regulatory pathways used by emerging regulatory authorities.
    Liberti L; Breckenridge A; Hoekman J; Leufkens H; Lumpkin M; McAuslane N; Stolk P; Zhi K; Rägo L
    J Public Health Policy; 2016 Aug; 37(3):315-333. PubMed ID: 26961261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.
    Dörr P; Wadworth A; Wang T; McAuslane N; Liberti L
    Ther Innov Regul Sci; 2016 Nov; 50(6):734-742. PubMed ID: 30231740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration-Designated Breakthrough and Nonbreakthrough Cancer Medicines.
    Hwang TJ; Franklin JM; Chen CT; Lauffenburger JC; Gyawali B; Kesselheim AS; Darrow JJ
    J Clin Oncol; 2018 Jun; 36(18):1805-1812. PubMed ID: 29688832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals.
    Herink MC; Irwin AN; Zumach GM
    Pharmacotherapy; 2018 Sep; 38(9):967-980. PubMed ID: 30043413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
    Kern KA
    J Oncol Pract; 2016 Aug; 12(8):e810-7. PubMed ID: 27460496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations.
    Daizadeh I
    Ther Innov Regul Sci; 2019 Mar; 53(2):264-269. PubMed ID: 29874936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.